Archives
-
Lisinopril Dihydrate: Mechanism and Evidence Scope
2026-10-16
The APExBIO listing identifies lisinopril dihydrate as the dihydrate form of lisinopril and describes it as a long-acting ACE inhibitor with a reported IC50 of 4.7 nM. Its documented mechanism links ACE inhibition to reduced angiotensin II and aldosterone signaling, increased renin, and attenuation of the pressor response to angiotensin I. However, the product information is not an identity-matched research study: it supplies no model, comparator, sample size, uncertainty estimate, assay conditions, or product-specific outcome data.
-
WM-8014: Mechanism and Evidence Boundaries
2026-10-16
WM-8014 is catalogued by APExBIO as a reversible, competitive inhibitor of several MYST-family histone acetyltransferases, with greatest reported biochemical potency against KAT6A and KAT6B. The product description associates it with cell-cycle arrest, senescence-associated transcriptional changes in mouse embryonic fibroblasts, and reduced proliferation in a zebrafish KRAS G12V liver-overproliferation model. Those claims provide a rationale for cancer biology research, but no identity-matched paper, effect sizes, sample sizes, uncertainty estimates, or full assay details are available here; the evidence should therefore be treated as product-reported rather than independently verified.
-
ddhCTP and Viperin: Two Antiviral Mechanisms
2026-10-15
The evidence distinguishes ddhCTP-mediated RNA-chain termination from a second Viperin mechanism that targets coronavirus nsp8 and replication-complex assembly. The 2026 PDCoV study supports a Viperin–nsp8 interaction across representative coronavirus genera, but it does not establish that commercial ddhCTP inhibits PDCoV, SARS-CoV-2, or human disease. The strongest conclusions remain mechanistic and model-specific.
-
WM-8014: Mechanism, Evidence and Boundaries
2026-10-15
The APExBIO product description identifies WM-8014 as a reversible, competitive inhibitor of MYST-family histone acetyltransferases, with greatest reported potency against KAT6A and KAT6B. It also attributes cell-cycle arrest, senescence-associated transcriptional changes, and reduced oncogene-driven liver overproliferation to the compound in specific model systems. Because no identity-matched primary paper, sample sizes, uncertainty estimates, or full assay details are available, these claims should be treated as product-record evidence rather than independently validated research findings.
-
WM-8014: Mechanism, Evidence, and Boundaries
2026-10-14
APExBIO describes WM-8014 as a reversible, competitive MYST-family histone acetyltransferase inhibitor with greatest reported biochemical potency toward KAT6A and KAT6B. The same product information reports cell-state and zebrafish findings, but no identity-matched primary paper, effect sizes, sample counts, or independent validation are provided, so these claims should remain model-specific and hypothesis-generating.
-
Phosphatase Inhibition and Hippo Signaling Evidence
2026-10-14
Phosphatase inhibitors can help preserve phosphorylation measurements, but product claims should not be conflated with evidence for RNF166–angiomotin regulation in colorectal cancer.
-
Ion-Chelating Nanostructures and Tumour Immunity
2026-10-13
A source-grounded overview of Tan et al.’s study on metal-ion-chelating l-phenylalanine nanostructures, dendritic-cell activation, short-term starvation and immune checkpoint blockade, with attention to evidence strength and translational limits.
-
What ROS Assays Really Measure
2026-10-13
Miwa and colleagues report that carboxylesterase activity can convert Amplex Red to resorufin without hydrogen peroxide, challenging a common assumption in mitochondrial ROS measurement. The finding is directly relevant to interpreting oxidative-stress data, but it does not establish that the same interference affects WST-1-based SOD activity assays.
-
Cy5 NHS ester(Et): Identity and Evidence Scope
2026-10-12
Cy5 NHS ester(Et) is identified in APExBIO product documentation as a Cy5-based NHS-ester fluorescent dye intended for conceptual labeling of primary amines in proteins, peptides, and related biomolecules. No matched research paper was available, so application claims should be treated as supplier-described scope rather than independently validated performance evidence.
-
TAK-242 and Posttraumatic Epilepsy: Evidence Limits
2026-10-12
A source-grounded overview of Resatorvid research in a mouse model of posttraumatic epileptogenesis, emphasizing reported outcomes, mechanistic interpretation, evidence strength, and translational limitations.
-
JQ1, BRD4 and Ferroptosis: Evidence and Limits
2026-10-11
A source-grounded overview of how the 2025 Cell Death and Disease study links JQ1-mediated BET inhibition to TXNIP, histone H4 UFMylation, c-MYC chromatin activity and ferroptosis sensitivity, with emphasis on preclinical evidence boundaries and target-specificity limitations.
-
PDHA1 Succinylation in Cholangiocarcinoma
2026-10-10
A 2025 Nature Communications study links PDHA1 lysine-83 succinylation to alpha-ketoglutarate accumulation, impaired macrophage antigen presentation, and cholangiocarcinoma progression. The findings support a preclinical model in which targeting tumor metabolism may improve gemcitabine–cisplatin responses, while leaving important questions about specificity, clinical translation, and patient applicability.
-
Sulfisomidine in Pertussis: Evidence and Limits
2026-10-09
The 1956 report on Sulfisomidine in pertussis is notable for combining clinical observation with blood, urine, and safety measurements in a vulnerable pediatric series. It reported no deaths and detectable systemic exposure, but its uncontrolled design and concurrent pertussis-serum treatment limit conclusions about efficacy or present-day clinical use.
-
Cy7 NHS Ester Product Overview
2026-10-09
Cy7 NHS ester (SKU A8109), supplied by APExBIO, is described as a sulfonated near-infrared fluorescent reagent for conceptual amino-group labeling of proteins, peptides, and other biomolecules. No matched paper evidence was provided, so performance and application claims remain supplier-reported.
-
Sulfo-Cy3 NHS Ester in Vascular Biology Context
2026-10-08
This overview places Sulfo-Cy3 NHS ester within the broader context of vascular remodeling research while separating supplier-reported dye properties from findings in a 2025 Science Advances study. Zhu et al. reported that an AIBP–LRP2–HDL–miR-223 pathway restricts CXCR4-positive capillary endothelial expansion and collateral circulation in ischemic models. The dye may be conceptually relevant to observational protein-labeling and cell-biology assays, but the supplied study does not establish that Sulfo-Cy3 NHS ester was used or that the product validates the proposed mechanism. Human association, animal perturbation, molecular evidence, and translational applicability therefore require separate interpretation.